PERSONALIZING CARE WITH TELEHEALTH
SOCIAL MEDIA BROADCAST FOUR

Bridging Distances in PAH:
Bringing Best Practices to the People Through Telementoring

Faculty

KATHARINE CLAPHAM, MD

Assistant Professor in Cardiology, Associate Director Pulmonary Hypertension and Dyspnea Program, Director of Pulmonary Vascular Research, University of Utah
Salt Lake City, UT
Jean Marie Elwing, MD, FCCP

Professor of Medicine, Director of Pulmonary Hypertension Program
University of Cincinnati Pulmonary
Madeira, OH

Program Overview

Pulmonary Arterial Hypertension (PAH) demands a personalized, multidisciplinary approach, encompassing specialized knowledge and novel treatments, a requisite often unfulfilled in remote regions due to significant gaps in access, expertise, and resources. The dearth of specialized PH centers and the ensuing reliance on general practitioners, compounded by geographical isolation from expansive medical communities, accentuates the urgency of integrating innovative treatments and the latest clinical trial data to enhance patient outcomes and refine risk management strategies.  Constrained resources in these areas further impede healthcare professionals' capacity to stay updated on groundbreaking guidelines, emergent therapies, and advancements in personalized, multidisciplinary care essential for managing PAH effectively. Complicating this scenario are prevailing technology and connectivity challenges, which curtail the adoption of telehealth initiatives and inhibit participation in telementoring programs — key conduits for disseminating knowledge on avant-garde therapies and clinical developments.  Consequently, a compelling need emerges for a strategic initiative, meticulously designed enable early detection, convey insights on current and novel treatments, disseminate pivotal clinical trial data, and elucidate strategies for individualized, multidisciplinary care to healthcare providers via telementoring. This initiative aspires to bridge the identified gaps, cultivate collaboration, and significantly elevate the standard of PAH management in underserved, resource-limited rural environments.   

Target Audience

This educational initiative is designed for pulmonologists, critical care, primary care physicians, nurse practitioners, physician assistants, surgeons, pharmacists, and nurses.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • EXPLAIN how to implement newly refined risk assessment tools into practice even in remote settings.
  • INTEGRATE telehealth and telementoring practices, ensuring consistent remote access to specialized multidisciplinary teams for optimal care of PAH patients.

Accreditation

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium Continuing Education (Iridium). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher


A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Disclosures

Disclosures of Relevant Financial Relationships


​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

KATHARINE CLAPHAM, MD
Consulting Fee (e.g., Advisory Board):
Amgen, Tectonic Therapeutics, United Therapeutics

JEAN MARIE ELWING, MD, FCCP
Consulting Fee (e.g., Advisory Board): United Therapeutics, Aerovate, Bayer, Gossamer Bio, Liquida, Acceleron/Merck, Janssen/Actelion/Johnson&Johnson, Roivant
Contracted Research (Principal Investigators must provide information, even if received by the institution): United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant, Aerovate, Pharmosa/Liquidia, Actelion/Janssen/Johnson&Johnson, Lung LLC, Riovant
Honoraria: United Therapeutics

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This educational activity is supported by independent educational grants from Merck Sharp & Dohme LLC and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Activity Credit Amount: 0.25
Maximum Credit Amount: 1.50
Credit Type: AMA
Release: August 29, 2024
Expiration: August 29, 2025